4.4 Article

Small molecule targeting NaV1.7 via inhibition of the CRMP2-Ubc9 interaction reduces pain in chronic constriction injury (CCI) rats

期刊

CHANNELS
卷 16, 期 1, 页码 1-8

出版社

TAYLOR & FRANCIS INC
DOI: 10.1080/19336950.2021.2023383

关键词

Chronic pain; NaV1; 7; CRMP2; SUMOylation; nociceptor; Ubc9

资金

  1. National Institutes of Health [NS098772, NS120663]
  2. NIDA (National Institute on Drug Abuse) [DA042852]
  3. National Institute of Neurological Disorders and Stroke [NS098772, NS120663]

向作者/读者索取更多资源

Recent studies have shown that compound 194, a small-molecule inhibitor of CRMP2 SUMOylation, selectively reduces NaV1.7 currents and reverses mechanical allodynia in various models of neuropathic pain. The efficacy of 194 in both traditional measures of pain behavior and operator-independent mechanical conflict-avoidance assay suggests its robust anti-nociception effect in alleviating mechanical allodynia associated with nerve injury.
The voltage-gated sodium channel isoform NaV1.7 is a critical player in the transmission of nociceptive information. This channel has been heavily implicated in human genetic pain disorders and is a validated pain target. However, targeting this channel directly has failed, and an indirect approach - disruption of interactions with accessory protein partners - has emerged as a viable alternative strategy. We recently reported that a small-molecule inhibitor of CRMP2 SUMOylation, compound 194, selectively reduces NaV1.7 currents in DRG neurons across species from mouse to human. This compound also reversed mechanical allodynia in a spared nerve injury and chemotherapy-induced model of neuropathic pain. Here, we show that oral administration of 194 reverses mechanical allodynia in a chronic constriction injury (CCI) model of neuropathic pain. Furthermore, we show that orally administered 194 reverses the increased latency to cross an aversive barrier in a mechanical conflict-avoidance task following CCI. These two findings, in the context of our previous report, support the conclusion that 194 is a robust inhibitor of NaV1.7 function with the ultimate effect of profoundly ameliorating mechanical allodynia associated with nerve injury. The fact that this was observed using both traditional, evoked measures of pain behavior as well as the more recently developed operator-independent mechanical conflict-avoidance assay increases confidence in the efficacy of 194-induced anti-nociception.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据